What were the demographics of mRNA vaccine trial participants? What races/ethnicities were included?

For the Pfizer-BioNTech vaccine (37,586 participants in safety population):

• Race/Ethnicity
  • 83.1% White (31,230)
  • 28.0% Hispanic/Latinx (10,522)
  • 9.1% Black (3,416)
  • 4.3% Asian (1,606)
  • 0.5% American Indian or Alaska Native (198)
  • 0.2% Native Hawaiian or other Pacific Islander (76) o
  • 2.3% Multiracial (853)
• Gender
  • 50.6% Male (19,001)
  • 49.4% Female (18,585)
• Age
  • Mean age 50.4 years

For the Moderna vaccine (30,350 participants in safety population):

• Race/Ethnicity
  • 79.2% White (24,023)
  • 20.5% Hispanic/Latinx (6,234)
  • 10.2% Black (3,090)
  • 4.6% Asian (1,385)
  • 0.8% American Indian or Alaska Native (230)
  • 0.2% Native Hawaiian or other Pacific Islander (66) o 2.1% Multiracial (634)
  • 2.1% Other (636)
• Gender
  • 52.7% Male (14,355)
  • 43.3% Female (13,175)
• Age
  • Mean age 51.4 years
  • 24.8% 65 years and older (7,520)

For the Johnson & Johnson vaccine (43,783 participants globally):

• Race/Ethnicity
  • 58.7% White
  • 45.3% Hispanic/Latinx
  • 19.4% Black
  • 3.3% Asian
  • 9.5% American Indian/Alaska Native
  • 0.2% Native Hawaiian or other Pacific Islander
  • 5.6% Multiracial
  • 1.4% Unknown
• Gender
  • 55% Male
  • 45% Female
• Age
  • Mean age 52 years
  • 34% 60 years and older (14,672)

Sources

• Pfizer Scientific Resources
• Moderna COVE Study
• FDA Pfizer-BioNTech
• FDA Moderna
• Johnson & Johnson

Updated: March 1, 2021